Many current molecular diagnostic COVID-19 tests rely on a nasopharyngeal swab, which can cause discomfort for patients during the collection process.
The new nasal swab collection option is more comfortable for patients and easier for healthcare providers to administer.
Nashville-based PathGroup operates in 25 states across the Southeast, Midwest and Mid-Atlantic regions, serving more than 100 hospitals and 15,000 referring physicians.
Since the COVID-19 pandemic began, PathGroup has also been working with state and local health departments to provide robust testing capabilities in communities across the region with many persons receiving test results within a 24-hour timeframe.
All of PathGroup's testing is performed on platforms that have received US Food and Drug Administration Emergency Use Authorization.
In addition to molecular diagnostic testing, PathGroup also offers serologic, or antibody, testing for COVID-19.
Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology laboratory services in the United States.
Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data